Scarica l'app Stockscreener
60.74
1.47%
0.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$59.86
Aprire:
$60.11
Volume 24 ore:
10.82M
Relative Volume:
0.76
Capitalizzazione di mercato:
$123.70B
Reddito:
$48.19B
Utile/perdita netta:
$7.06B
Rapporto P/E:
17.56
EPS:
3.4587
Flusso di cassa netto:
$12.85B
1 W Prestazione:
-2.02%
1M Prestazione:
+8.62%
6M Prestazione:
+26.94%
1 anno Prestazione:
+8.52%
Intervallo 1D:
$60.02
$60.95
Intervallo di 1 settimana:
$59.25
$61.63
Portata 52W:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.74 | 121.90B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers (BMY) Receives FDA Orphan Drug Status for Follicul - GuruFocus
Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Finviz
Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb signs to Life Science Cares National Campaign to advance health equity and fight food insecurity - ROI-NJ
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
LSV Asset Management Purchases 138,119 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Rhumbline Advisers - MarketBeat
Krilogy Financial LLC Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (NYSE:BMY) Given Average Rating of "Hold" by Brokerages - MarketBeat
Illinois Municipal Retirement Fund Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Caisse Des Depots ET Consignations Sells 21,113 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth - Insider Monkey
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb's Q4 Earnings Call - Finviz
What Does the Market Think About Bristol-Myers Squibb Co? - Sahm
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
BRISTOL MYERS SQUIBB CO SEC 10-K Report - TradingView
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
SC refuses stay on Zydus cancer drug launch, tells BMS to seek relief in HC - Business Standard
Wealthfront Advisers LLC Sells 17,324 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Oral Anticoagulants Market Is Going to Boom |• Bristol-Myers Squibb • Johnson & Johnson - openPR.com
ING Groep NV Boosts Position in Bristol Myers Squibb Company $BMY - MarketBeat
Hepatitis B Treatment Market Size is Projected to Reach USD 7.74 Billion by 2033 Due to the Increasing Disease Management Trends Globally - GlobeNewswire Inc.
Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents - The Economic Times
Bristol Myers Squibb’s Stock Is On Sale: Value Trap Or Deep-Value Turnaround Play? - AD HOC NEWS
Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound? - Yahoo Finance
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline OutlookHas The Bull Case Changed? - Yahoo Finance
Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation - Yahoo Finance
Bristol-Myers Squibb (BMY) Is Up 8.7% After Swing To Profit And AI-Focused R&D Push - simplywall.st
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Bristol Myers Squibb Company $BMY Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Candriam S.C.A. Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance
Kinsale Capital Group Inc. Has $7.61 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):